Key result
Recombinant human thrombopoietin induced tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and augmented ADP-induced platelet aggregation in a dose-dependent manner in vitro.
TPO modulates platelet activation through protein-tyrosine phosphorylation and enhances agonist-induced aggregation.
Answers are grounded in this paper and cite their sources.
May enhance platelet reactivity via JAK/STAT; leaves open clinical thrombotic relevance pending in vivo studies.
We investigated in vitro effects of recombinant human thrombopoietin (TPO), or c-Mpl ligand, on human platelets. TPO induced rapid dose-dependent tyrosine phosphorylation of several proteins. We identified Janus tyrosine kinases, Tyk2 and JAK2, and a member of STAT (signal transducers and activators of transcription) family, STAT3, as the tyrosine-phosphorylated proteins in response to TPO. TPO by itself did not cause platelet aggregation and shape change, but augmented ADP-induced aggregation in a dose-dependent manner. Acetylsalicylic acid inhibited the secondary aggregation enhanced by TPO, but not the TPO-induced potentiation of the primary aggregation. TPO modulates platelet activation possibly through protein-tyrosine phosphorylation.
No takes yet. Share an insight, caveat, or question.
Ezumi et al. (1995) studied In vitro human platelets. Recombinant human thrombopoietin (TPO) was evaluated on Tyrosine phosphorylation and platelet aggregation. Recombinant human thrombopoietin induced tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and augmented ADP-induced platelet aggregation in a dose-dependent manner in vitro.
Synapse has enriched 10 related papers. Consider them for comparative context: